The company said members of its executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m. ET.

8-KRegulation FD DisclosureFiled Sep 3, 2024Period of report Sep 3, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said members of its executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m. ET.
The company disclosed its participation in the conference under Item 7.01, Regulation FD Disclosure, of this 8-K, and attached as Exhibit 99.1 a press release dated September 3, 2024.
The company said more than 67,000 employees serve clients in approximately 100 countries.
The company said it provided support for 84% of the new drugs and therapeutic products approved by the FDA in 2023 and performed more than 600 million tests for patients around the world.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Labcorp to Speak at the Baird 2024 Global Healthcare Conference

The company said members of its executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m. ET.

Source · Based on the filing body and exhibits

Item 7.01 Regulation FD Disclosure and Press Release Attached

The company disclosed its participation in the conference under Item 7.01, Regulation FD Disclosure, of this 8-K, and attached as Exhibit 99.1 a press release dated September 3, 2024.

Source · Based on the filing body and exhibits

Employee Headcount and Service Regions

The company said more than 67,000 employees serve clients in approximately 100 countries.

Source · Based on the filing body and exhibits

Support for FDA-Approved Drugs and Tests Performed in 2023

The company said it provided support for 84% of the new drugs and therapeutic products approved by the FDA in 2023 and performed more than 600 million tests for patients around the world.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.